Comparative Pharmacology
Head-to-head clinical analysis: PROVOCHOLINE versus VUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROVOCHOLINE versus VUITY.
PROVOCHOLINE vs VUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours in patients with normal renal function. However, due to rapid hydrolysis by plasma and tissue cholinesterases, the actual duration of effect is brief (minutes). Clinical context: half-life may be prolonged in patients with reduced cholinesterase activity or renal impairment.
Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months.
Primarily renal excretion of unchanged drug and inactive metabolites. Approximately 80-90% of administered dose is excreted renally. No significant biliary or fecal elimination.
Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%).
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist